Plastic changes and disease-modifying effects of scopolamine in the pilocarpine model of epilepsy in rats

被引:11
|
作者
Pereira, HAA
Benassi, SK
Mello, LE
机构
[1] Univ Fed Sao Paulo, Dept Physiol, BR-04023062 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Psychobiol, BR-04023062 Sao Paulo, Brazil
关键词
status epilepticus; hippocampus; temporal lobe epilepsy; pilocarpine; scopolamine; plasticity; antiepileptogenesis;
D O I
10.1111/j.1528-1167.2005.01017.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: We describe the use of a clinically relevant pharmacological intervention that alters the clinical history of status epilepticus (SE)-induced spontaneous recurrent seizures (SRS) in the pilocarpine model and the possible plastic changes underlying such an effect. Methods: Two hours after pilocarpine-induced SE (320-350 mg/kg, i.p.), rats received scopolamine 1-2 mg/kg i.p. or saline, every 6 h for 3 days. After that, osmotic minipumps were implanted for continuous delivery of scopolainine or saline for an additional 14 days. Animals were video-monitored for 12 h/week during the following 3-month period for the occurrence of SRS and, thereafter, were perfused, processed, and coronal brain sections were stained for acetylcholinesterase (AChE) and for the presence of supragranular mossy fibers (Timm), Results: Treatment with scopolamine led to significantly fewer SRS. Staining for AChE in the dentate gyrus was significantly more intense in naive animals. The scopolamine group had the least intense AChE staining of all groups. However, regression analysis of the AChE staining for this group did not correlate with the presence or absence of SRS, or the latency or frequency of SRS. Supragranular mossy fiber sprouting developed in all animals experiencing pilocarpine-induced SE, irrespective of whether or not they were treated with scopolamine. Conclusions: Pilocarpine-induced SE in the presence of scopolamine might produce animals that, despite mossy fiber sprouting, were not seen to exhibit spontaneous seizures. In addition, our data suggest that the encountered changes in the AChE staining in the dentate gyrus that followed treatment with scopolamine do not help to explain its disease-modifying effects.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 50 条
  • [41] A Combination of Levetiracetam and Topiramate Exerts Disease-Modifying Effects in the Intrahippocampal Kainate Mouse Model
    Schidlitzki, A.
    Twele, F.
    Toellner, K.
    Loescher, W.
    EPILEPSIA, 2018, 59 : S21 - S21
  • [42] Effects of herbimycin A in the pilocarpine model of temporal lobe epilepsy
    de Queiroz, CMT
    Mello, LE
    BRAIN RESEARCH, 2006, 1081 : 219 - 227
  • [43] Neuroinfl ammatory Processes Affect Structural Changes in the Amygdala of Rats in a Lithium-Pilocarpine Model of Epilepsy
    Vasilev D.S.
    Tumanova N.L.
    Kovalenko A.A.
    Zubareva O.E.
    Kalemenev S.V.
    Magazanik L.G.
    Neuroscience and Behavioral Physiology, 2020, 50 (5) : 625 - 632
  • [44] Methods for discerning disease-modifying effects in Alzheimer disease treatment trials
    Kaye, JA
    ARCHIVES OF NEUROLOGY, 2000, 57 (03) : 312 - 314
  • [45] Disease-Modifying Effects of Transplanted Fetal GABAergic Progenitors in Mice With Temporal Lobe Epilepsy and Spontaneous Recurrent Seizures
    Litvina, E.
    Tagliatela, S.
    Maisano, S.
    Woods, N.
    Evans, E.
    Seo, L.
    Naegele, J.
    CELL TRANSPLANTATION, 2011, 20 (04) : 570 - 571
  • [46] Disease-modifying potential of diphenyl diselenide in an experimental osteoarthritis model
    Qiao, Li
    Li, Zhiyao
    Shi, Peihua
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 710
  • [47] Assessing long-term effects of disease-modifying drugs
    Kieseier, Bernd C.
    JOURNAL OF NEUROLOGY, 2006, 253 (Suppl 6) : 23 - 30
  • [48] Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis
    Reddy, Doodipala Samba
    Gangisetty, Omkaram
    Briyal, Seema
    NEUROPHARMACOLOGY, 2010, 59 (7-8) : 573 - 581
  • [49] Disease-modifying effects of ranibizumab for central retinal vein occlusion
    Jason M. Huang
    Rahul N. Khurana
    Avanti Ghanekar
    Pin-wen Wang
    Bann-Mo Day
    Barbara A. Blodi
    Amitha Domalpally
    Carlos Quezada-Ruiz
    Michael S. Ip
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 799 - 805
  • [50] Assessing long-term effects of disease-modifying drugs
    Bernd C. Kieseier
    Journal of Neurology, 2006, 253 : vi23 - vi30